Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-26
2010-10-05
Kam, Chih-mln (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S384000, C424S009100
Reexamination Certificate
active
07807639
ABSTRACT:
The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject. Methods of the present invention are useful in treating diffuse alveolar hemorrhage secondary to blast lung injury, HIV infection and AIDS.
REFERENCES:
patent: 3920845 (1975-11-01), Smith et al.
patent: 5096916 (1992-03-01), Skupin
patent: 5427797 (1995-06-01), Frostell et al.
patent: 5690910 (1997-11-01), Ahmed et al.
patent: 5980865 (1999-11-01), Ahmed
patent: 6193957 (2001-02-01), Ahmed
patent: 6497877 (2002-12-01), Stringer et al.
patent: 2003/0054018 (2003-03-01), Hedner
patent: 2003/0195141 (2003-10-01), Mathison
patent: 2004/0265238 (2004-12-01), Chaudry
patent: 2005/0008580 (2005-01-01), Gong et al.
patent: 2005/0059590 (2005-03-01), Pan et al.
de Gracia et al. Use of endoscopic fibrinogen-thrombin in the treatment of severe hemoptysis. (Apr. 2003) vol. 97: 790-795.
de Gracia et al., “The use of fibrinogen-thrombin via endoscope in the treatment of massive hemoptysis”, Arch Bronconeumol. 1995 31(5):27-232 (Abstract only).
de Gracia et al., “Use of endoscopic fibrinogen-thrombin in the treatment of severe hemoptysis”, Respir Med. 2003 97(7):790-795 (Abstract only).
Henke et al., “Successful Treatment of Diffuse Alveolar Hemorrhage with Activated Factor VII”, Annals of Internal Medicine 2004 140(6):493-494.
Hosoda et al., “A frequent fiber-scopic bronchial lavage for the case of bilateral sever pulmonary contusion with flail chest”, Kyobu Geka. 2001 54(4):352-354 (Abstract only).
Pastores et al., “Diffuse Alveolar Hemorrhage After Allogeneic Hematopoietic Stem-Cell Transplantation”, Chest 2003 124:2400-2403.
Saito et al., “Pulmonary pseudallescheriasis in a patient with diabetes mellitus and alcoholic liver cirrhosis”, Nihon Kokyuki Gakkai Zasshi 1998 36(5):498-502 (Abstract only).
Betensley et al., “Factor VIIa for Alveolar Hemorrhage in Microscopic Polyangitis”, American Journal of Respiratory and Critical Care Medicine 2002 166:1291-129.
Dvilansky et al., “Factor XIII Assay by an Isotope Method—I. Factor XIII (Transamidase) in Plasma, Serum, Leucocytes, Erythrocytes and Platelets and Evaluation of Screening Tests of Clot Solubility”, British Journal of Haematology 1970 18:399-410.
Ghorashian et al., “Off-license” use of recombinant activated factor VII, Blood Reviews 2004 18:245-259.
Tsukamoto et al., “Treatment of Hemoptysis Patients by Thrombin and Fibrinogen-Thrombin Infusion Therapy Using a Fiberoptic Bronchoscope”, Chest 1989 96(3):473-476.
Olschewski et al., “Inhaled iloprost for severe pulmonary hypertension”, N. Engl J Med 2002 347(5):322-329.
Diringer et al., “Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage”, Stroke 2008 39:850-856.
Gomberg-Maitland et al., “Prostacyclin therapies for the treatment of pulmonary arterial hypertension”, Eur Respir J 2008 31:891-901.
Levy et al., “Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury:review of safety profile”, Transfusion 2006 46:919-933.
Mantzios et al. et al., “Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding”, European Journal of Haematology 2007 78:173-174.
Mazer et al., “Vascular injury and thrombotic potential:a note of caution about recombinant factor VIIa”, Seminars in Cardiothoracic and Vascular Anesthesia 2007 11(4):261-264.
O'Connell et al., “Thromboembolic adverse events after use of recombinant human coagulation factor VIIa”, JAMA 2006 295(3):293-298.
Powell et al., “Inhaled corticosteroid doses in asthma:an evidence-based approach”, MJA 2003 178:223-225.
Cheer et al., “Inhaled tobramycin (TOBI) A review of its use in the management ofPseudomonas aeruginosainfections in patients with cystic fibrosis”, Drugs 2003 63(22):2501-2520.
Palmer et al., “Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit”, Crit Care Med 2008 36(7):2008-2013.
Waldeck, Bertil, “β-adrenoceptor agonists and asthma-100 years of development”, European Journal of Pharmacology 2002 445:1-12.
Berntorp, E. “Recombinant FVIIa in the Treatment of Warfarin Bleeding” Seminars in Thrombosis and Hemostasis 2000 vol. 26(4): 433-435.
Diness et al. “Effect of Recombinant Human FVIIa on Warfarin-Induced Bleeding in Rats” Thrombosis Research 1990 vol. 59: 921-929.
Diness et al. “Recombinant Human Factor VIIa (rFVIIa) in a Rabbit Stasis Model” Thrombosis Research 1992 vol. 67: 233-241.
Holmberg et al. “Faster Onset of Effect and Greater Efficacy of NN1731 Compared with rFVIIa, aPCC and FvIII in Tail Bleeding in Hemophilic Mice” Journal of Thrombosis and Haemostasis 2009 vol. 7: 1517-1522.
Lauritzen et al. “Recombinant Human Factor VIIa and a Factor VIIa-Analogue Reduces Heparin and Low Molecular Weight Heparin (LMWH)-Induced Bleeding in Rats” Journal of Thrombosis and Haemostasis 2008 vol. 6: 804-811.
Chen et al. “Efficacy of Zymogen Factor VII Is Comparable to Activated Factor VII for Nonviral Gene Therapy Treatment of Hemophilia A” Blood 2005 vol. 106: Abstract 5543.
Emeis et al. “A Guide to Murine Coagulation Factor Structure, Function, Assays, and Genetic Alterations” Journal of Thrombosis and Haemostasis vol. 5: 670-679, (2007).
Petersen et al. “Characterization of Recombinant Murine Factor VIIa and Recombinant Murine Tissue Factor: A Human-Murine Species Compatibility Study” Thrombosis Research 2005 vol. 116: 75-85.
Petersen et al. “Plasma Elimination Kinetics for Factor VII Are Independent of Its Activation to Factor VIIa and Complex Formation with Plasma Inhibitors” Thrombosis and Haemostasis 2009 vol. 101: 818-826.
Heslet Lars
Uttenthal Lars Otto
Kam Chih-mln
Licata & Tyrrell P.C.
Pharmaorigin ASP
LandOfFree
Methods for preventing and treating local tracheal,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing and treating local tracheal,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing and treating local tracheal,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179303